4D Molecular Therapeutics Inc
FDMT
Company Profile
Business description
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Contact
5858 Horton Street
Suite 455
EmeryvilleCA94608
USAT: +1 510 505-2680
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
196
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 17.10 | -0.18% |
| CAC 40 | 8,332.87 | 54.28 | 0.66% |
| DAX 40 | 26,662.77 | 315.32 | 1.20% |
| Dow JONES (US) | 52,486.49 | 254.60 | 0.49% |
| FTSE 100 | 10,835.47 | 83.88 | 0.78% |
| HKSE | 24,065.72 | 250.20 | -1.03% |
| NASDAQ | 25,466.19 | 400.32 | 1.60% |
| Nikkei 225 | 60,708.68 | 539.91 | -0.88% |
| NZX 50 Index | 14,259.23 | 79.37 | 0.56% |
| S&P 500 | 7,619.38 | 98.45 | 1.31% |
| S&P/ASX 200 | 9,146.80 | 6.40 | -0.07% |
| SSE Composite Index | 3,660.57 | 20.07 | -0.55% |